NCT05733611 Phase 2 Terminated
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC Study sponsor: Replimune, Inc.
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-08-18 Actual
Enrollment · participants 5 Actual
Source updated 2026-02-02 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-02-02 · 4 fields changed
Actual enrollment increased by 1 participants
− Before 4 participants (actual)
+ After 5 participants (actual)
Completion date type changed
Primary completion date changed
Recruitment status changed
− Before Active not recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial